Discussion
OSA
We recently demonstrated that one-week bedtime administration of reboxetine plus oxybutynin reduces OSA severityOur results show that one-week administration of reboxetine plus oxybutynin: (i) did not increase BP during the day or the night; (ii) did not enhance cardiac sympathetic modulation as reflected by nighttime HRV; (iii) did not impair but rather increased the sensitivity of the baroreflex control of heart rate; and (iv) decreased the baroreflex resonance in BP spectra, a surrogate measure for the vascular sympathetic modulation. To date, this is the first evaluation of the impact of the new OSA pharmacologic therapy on cardiovascular autonomic regulation.Reboxetine is highly selective for norepinephrine transporters and has a low affinity with muscarinic, histamine-H1, and adrenergic α1 receptors